Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
|Articles|August 1, 2011
Pharmaceutical Technology Europe
- Pharmaceutical Technology Europe-08-01-2011
- Volume 23
- Issue 8
Understanding Fluidized-Bed Granulation
This study demonstrates the beneficial use of a spatial-filter velocimetry particle-size analyzer during granulation.
Advertisement
By A. Burggraeve, T. Van Den Kerkhof, M. Hellings, J.P. Remon, C. Vervaet and T. De Beer
The authors incorporated a particle-size analyser into a laboratory-scale top-spray fluid-bed granulator to monitor granule size distribution (GSD) continuously during granulation. A two-level full-factorial design was used to study the influence of several process and formulation variables on the end-product GSD, measured in-line with spatial-filter velocimetry (SFV).
This article was also published in our US sister publication Pharmaceutical Technology and can be read
Articles in this issue
about 15 years ago
Improving API Synthesisabout 15 years ago
Controlled Release from Porous Platformsabout 15 years ago
Controlled Crystallization During Freeze-Dryingabout 15 years ago
Movin' On Outabout 15 years ago
The Many Varieties Of 'Emerging'about 15 years ago
Newsabout 15 years ago
Managing Information Overloadabout 15 years ago
The Importance Of Filter Testingabout 15 years ago
Making A Mark In Emerging Marketsabout 15 years ago
Croatia, Pharma and CorruptionAdvertisement
Related to this article
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
This article discusses risk-based lifecycle governance, system implementation considerations, and the progression of batch record control from paper-based to fully electronic systems.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Tavapadon Sets Development Benchmark for Parkinson's
2
KRAS G12D Inhibitor's $2.13B Deal Tests Cross-Border Tech Transfer
3
Weekly Basal Insulin Efsitora: A New Biologics CMC Benchmark
4
PharmTech’s Weekly Roundup—September 25, 2026
5